IL105472A - Medicinal composition for suppressing T-cell proliferation and immune response to foreign tissue transplantation, containing antigens from the primary type II transplant antigen complex or synthetic peptides - Google Patents

Medicinal composition for suppressing T-cell proliferation and immune response to foreign tissue transplantation, containing antigens from the primary type II transplant antigen complex or synthetic peptides

Info

Publication number
IL105472A
IL105472A IL10547293A IL10547293A IL105472A IL 105472 A IL105472 A IL 105472A IL 10547293 A IL10547293 A IL 10547293A IL 10547293 A IL10547293 A IL 10547293A IL 105472 A IL105472 A IL 105472A
Authority
IL
Israel
Prior art keywords
mammal
class
peptide
antigen
histocompatibility complex
Prior art date
Application number
IL10547293A
Other languages
English (en)
Hebrew (he)
Other versions
IL105472A0 (en
Original Assignee
Autoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autoimmune Inc filed Critical Autoimmune Inc
Publication of IL105472A0 publication Critical patent/IL105472A0/xx
Publication of IL105472A publication Critical patent/IL105472A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
IL10547293A 1992-04-20 1993-04-20 Medicinal composition for suppressing T-cell proliferation and immune response to foreign tissue transplantation, containing antigens from the primary type II transplant antigen complex or synthetic peptides IL105472A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US87128992A 1992-04-20 1992-04-20
US96177992A 1992-10-15 1992-10-15
US97773792A 1992-11-13 1992-11-13
US08/027,127 US5593698A (en) 1990-10-31 1993-03-05 Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides

Publications (2)

Publication Number Publication Date
IL105472A0 IL105472A0 (en) 1993-08-18
IL105472A true IL105472A (en) 1999-06-20

Family

ID=27487557

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10547293A IL105472A (en) 1992-04-20 1993-04-20 Medicinal composition for suppressing T-cell proliferation and immune response to foreign tissue transplantation, containing antigens from the primary type II transplant antigen complex or synthetic peptides

Country Status (13)

Country Link
US (1) US5593698A (pt)
EP (1) EP0637249B1 (pt)
JP (1) JPH07505892A (pt)
KR (1) KR100275656B1 (pt)
AT (1) ATE205400T1 (pt)
AU (1) AU686101B2 (pt)
BR (1) BR9306345A (pt)
CA (1) CA2118502A1 (pt)
DE (1) DE69330752D1 (pt)
HU (1) HUT71310A (pt)
IL (1) IL105472A (pt)
NO (1) NO943967L (pt)
WO (1) WO1993020842A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US6156306A (en) * 1994-08-17 2000-12-05 Albert Einstein College Of Medicine Of Yeshiva University Pancreatic β-cells for allogeneic transplantation without immunosuppression
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
US7361331B2 (en) * 1996-10-18 2008-04-22 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food Plant bioreactors
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
US7348005B2 (en) * 2000-03-15 2008-03-25 Advanced Research And Technology Institute Oral tolerance induction by collagen to prevent allograft rejection
WO2001076617A2 (en) * 2000-03-15 2001-10-18 Advanced Research And Technology Institute Oral tolerance induction by collagen to prevent allograft rejection
EP2295067A1 (en) 2000-05-24 2011-03-16 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services E-selectin for inducing immunotolerance
HU229377B1 (hu) * 2000-08-21 2013-11-28 Apitope Technology Bristol Ltd Tolerogén humán peptidek
US7582313B2 (en) * 2002-06-27 2009-09-01 The General Hospital Corporation Methods of organ regeneration using Hox 11-expressing pluripotent cells
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
WO2004045376A2 (en) * 2002-11-15 2004-06-03 The General Hospital Corporation Screening methods to identify treatments for autoimmune disease
US20080102054A1 (en) * 2005-01-18 2008-05-01 Faustman Denise L Compositions Containing Agm Cells And Methods Of Use Thereof
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
PL2083856T3 (pl) 2007-08-15 2011-04-29 Circassia Ltd Peptydy do odczulania na alergeny
WO2014124134A1 (en) 2013-02-07 2014-08-14 The General Hospital Corporation Methods for expansion or depletion of t-regulatory cells
WO2015150492A2 (en) * 2014-04-01 2015-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) An isolated donor mhc-derived peptide and uses thereof
ES2962885T3 (es) 2015-05-15 2024-03-21 Massachusetts Gen Hospital Anticuerpos antagonistas de la superfamilia del receptor del factor de necrosis tumoral
WO2017059132A1 (en) 2015-09-29 2017-04-06 The General Hospital Corporation Methods of treating and diagnosing disease using biomarkers for bcg therapy
WO2017197331A2 (en) 2016-05-13 2017-11-16 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364762A (en) * 1990-03-21 1994-11-15 Board Of Trustees Of The Leland Stanford Junior University Major histocompatibility complex (MHC) molecules

Also Published As

Publication number Publication date
KR950701228A (ko) 1995-03-23
US5593698A (en) 1997-01-14
BR9306345A (pt) 1998-06-30
EP0637249A4 (en) 1997-01-08
AU4108393A (en) 1993-11-18
IL105472A0 (en) 1993-08-18
NO943967D0 (no) 1994-10-19
WO1993020842A1 (en) 1993-10-28
JPH07505892A (ja) 1995-06-29
EP0637249A1 (en) 1995-02-08
KR100275656B1 (ko) 2000-12-15
HUT71310A (en) 1995-11-28
AU686101B2 (en) 1998-02-05
CA2118502A1 (en) 1993-10-28
NO943967L (no) 1994-10-19
ATE205400T1 (de) 2001-09-15
HU9403006D0 (en) 1994-12-28
EP0637249B1 (en) 2001-09-12
DE69330752D1 (de) 2001-10-18

Similar Documents

Publication Publication Date Title
US5593698A (en) Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides
Sayegh et al. Role of indirect allorecognition in allograft rejection
SAYEGH et al. Thymic recognition of class II major histocompatibility complex allopeptides induces donor-specific unresponsiveness to renal allografts
Allez et al. Regulatory T cells: peace keepers in the gut
US5681556A (en) Method and compositions for suppressing allograft rejection in mammals
Dong et al. Transplantation tolerance: the concept and its applicability
CA2110055C (en) T cell receptor peptides as therapeutics for immune-related disease
Miller et al. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein VI. Suppression of adoptively transferred disease and differential effects of oral vs. intravenous tolerization
Miller et al. Tolerance and suppressor mechanisms in experimental autoimmune encephalomyelitis: implications for immunotherapy of human autoimmune diseases
Brouard et al. T cell response in xenorecognition and xenografts: a review
Zavazava et al. Oral feeding of an immunodominant MHC donor-derived synthetic class I peptide prolongs graft survival of heterotopic cardiac allografts in a high-responder rat strain combination
Chowdhury et al. Comparative studies of specific acquired systemic tolerance induced by intrathymic inoculation of a single synthetic Wistar-Furth (RT1u) allo-MHC class I (RT1. AU) peptide or WAG (RT1u)-derived class I peptide1
Murphy et al. T CELL RECOGNITION OF XENO-MHC PEPTIDES DURING CONCORDANT XENOGRAFT REJECTION1
Kelley et al. Renal tubular epithelial and T cell interactions in autoimmune renal disease.
Saitovitch et al. RECIPIENT CELLS EXPRESSING SINGLE DONOR MHC LOCUS PRODUCTS CAN SUBSTITUTE FOR DONOR-SPECIFIC TRANSFUSION IN THE INDUCTION OF TRANSPLANTATION TOLERANCE WHEN PRETREATMENT IS COMBINED WITH ANTI-CD4 MONOCLONAL ANTIBODY: Evidence for a Vital Role of Cd4:+: T Cells in the Induction of Tolerance to Class I Molecules: 1:: 2
NOEL The immune response in autoimmunity and autoimmune disease
Kroemer et al. The fail-safe paradigm of immunological self-tolerance
Oluwole et al. CD4+ CD25+ regulatory T cells mediate acquired transplant tolerance
Saborio et al. Regulatory T cells maintain peripheral tolerance to islet allografts induced by intrathymic injection of MHC class I allopeptides
EP0883406A1 (fr) Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant
Masroor et al. Induction of tolerance in rodent cardiac allotransplantation using an MHC class I-derived peptide and cyclosporin A
Ten Berge et al. A longitudinal study on the effects of azathioprine and high doses of prednisone on the immune system of kidney-transplant recipients
Kozovska et al. TT cellular interaction between CD4-CD8-regulatory T cells and T cell clones presenting TCR peptide. Its implication for TCR vaccination against experimental autoimmune encephalomyelitis.
Murphy et al. Immunomodulatory function of major histocompatibility complexderived peptides
Benichou et al. The influence of two distinct alloresponse pathways on the design of peptide-based strategies for allograft tolerance

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees